{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:45:14Z","timestamp":1762375514737},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.diagmicrobio.2011.03.009","type":"journal-article","created":{"date-parts":[[2011,6,24]],"date-time":"2011-06-24T22:44:42Z","timestamp":1308955482000},"page":"367-372","source":"Crossref","is-referenced-by-count":36,"title":["The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study"],"prefix":"10.1016","volume":"70","author":[{"given":"Yehuda","family":"Carmeli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiri Klarfeld","family":"Lidji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Shabtai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiri","family":"Navon-Venezia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell J.","family":"Schwaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1128\/AAC.50.1.43-48.2006","article-title":"Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact","volume":"50","author":"Aloush","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0010","first-page":"857","article-title":"Appropriate use of the carbapenems","volume":"94","author":"Brink","year":"2004","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00001432-199708000-00008","article-title":"The quality of antibiotic use and the quality of measuring it","volume":"10","author":"Burke","year":"1997","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0020","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1128\/JCM.36.2.595-597.1998","article-title":"Failure of quality control measures to prevent reporting of false resistance to imipenem, resulting in a pseudo-outbreak of imipenem-resistant Pseudomonas aeruginosa","volume":"36","author":"Carmeli","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0025","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3201\/eid0808.010418","article-title":"Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus","volume":"8","author":"Carmeli","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0030","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1128\/AAC.43.6.1379","article-title":"Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents","volume":"43","author":"Carmeli","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2006.07.011","article-title":"First national surveillance of susceptibility of extended-spectrum beta-lactamase\u2013producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel","volume":"57","author":"Colodner","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0040","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1086\/375081","article-title":"The impact of antimicrobial resistance on health and economic outcomes","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0045","article-title":"Effect of ertapenem utilization on Pseudomonas aeruginosa susceptibility to imipenem","author":"Crank","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ajic.2005.12.011","article-title":"Surgical site infection in patients submitted to digestive surgery: risk prediction and the NNIS risk index","volume":"34","author":"de Oliveira","year":"2006","journal-title":"Am. J. Infect. Control"},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.diagmicrobio.2007.03.016","article-title":"Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative trials of ertapenem therapy","volume":"58","author":"DiNubile","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0060","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1128\/AAC.49.8.3217-3221.2005","article-title":"Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections","volume":"49","author":"DiNubile","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0065","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10096-005-1356-0","article-title":"Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy","volume":"24","author":"DiNubile","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jinf.2008.06.001","article-title":"Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem","volume":"57","author":"Goff","year":"2008","journal-title":"J. Infection."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0075","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/AAC.00064-09","article-title":"Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa","volume":"53","author":"Goldstein","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0080","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijantimicag.2006.04.010","article-title":"In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)","volume":"28","author":"Hsueh","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0085","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1128\/AAC.00060-06","article-title":"Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa","volume":"50","author":"Kaye","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0090","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/jac\/dki009","article-title":"Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems","volume":"55","author":"Livermore","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0095","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.289.7.885","article-title":"Antibiotic resistance among gram-negative bacilli in US intensive care units. Implications for fluoroquinolone use","volume":"289","author":"Neuhauser","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0100","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/01.CCM.0000153527.76103.EF","article-title":"Reexamining quinolone use in the intensive care unit: use them right or lose the fight against resistant bacteria","volume":"33","author":"Niederman","year":"2005","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0105","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/381550","article-title":"Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity","volume":"38","author":"Paramythiotou","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0110","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1469-0691.2000.00107.x","article-title":"Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs)","volume":"6","author":"Paterson","year":"2000","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 4","key":"10.1016\/j.diagmicrobio.2011.03.009_bb0115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1086\/382690","article-title":"Collateral damage from cephalosporin or quinolone antibiotic therapy","volume":"38","author":"Paterson","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum b-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/infdis\/154.2.289","article-title":"Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections","volume":"154","author":"Quinn","year":"1986","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0130","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/jac\/dkl354","article-title":"Two decades of imipenem therapy","volume":"58","author":"Rodloff","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0135","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/jac\/dkm318","article-title":"Mortality and delay in effective therapy associated with extended-spectrum {beta}-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis","volume":"60","author":"Schwaber","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0140","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nrmicro1047","article-title":"Epidemiological interpretation of antibiotic resistance studies - what are we missing?","volume":"2","author":"Schwaber","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0145","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jac\/dkg404","article-title":"Ertapenem, the first of a new group of carbapenems","volume":"52","author":"Shah","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0150","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1473-3099(07)70082-8","article-title":"The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection","volume":"7","author":"Stone","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0155","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.01509-06","article-title":"Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment","volume":"51","author":"Tumbarello","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.03.009_bb0160","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3201\/eid0911.030284","article-title":"Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients","volume":"9","author":"Weber","year":"2003","journal-title":"Emerg. Infect. Dis."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889311001027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889311001027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T17:16:52Z","timestamp":1592673412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889311001027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0732889311001027"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2011.03.009","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}